CHMP Recommends Earlier-Line Use of Talvey (Talquetamab) Plus Daratumumab for Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/chmp-recommendation-talquetamab-daratumumab-rrmm)